SEARCH

SEARCH BY CITATION

References

  • 1
    Gale EA. The rise of childhood Type 1 diabetes in the 20th century. Diabetes 2002; 51: 33533361.
  • 2
    Gale EA. Spring harvest? Reflections on the rise of Type 1 diabetes. Diabetologia 2005; 48: 24452450.
  • 3
    Peng H, Hagopian W. Environmental factors in the development of Type 1 diabetes. Rev Endocr Metab Disord 2006; 7: 149162.
  • 4
    Ludvigsson J. Why diabetes incidence increases—a unifying theory. Ann N Y Acad Sci 2006; 1079: 374382.
  • 5
    Gianani R, Eisenbarth GS. The stages of Type 1A diabetes: 2005. Immunol Rev 2005; 204: 232249.
  • 6
    Bach JF, Chatenoud L. Tolerance to islet autoantigens in Type 1 diabetes. Annu Rev Immunol 2001; 19: 131161.
  • 7
    Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI et al . Insulin secretion in Type 1 diabetes. Diabetes 2004; 53: 426433.
  • 8
    Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14: 619633.
  • 9
    Daneman D, Clarson C. Residual β-cell function in children with Type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med 1987; 10: 484487.
  • 10
    The Diabetes Control and Complications Trial Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65: 3036.
  • 11
    The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with Type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517523.
  • 12
    Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832836.
  • 13
    Chase HP, MacKenzie TA, Burdik J, Fiallo-Scharer R, Walravens P, Klingensmith G et al . Redefining the clinical remission period in children with Type 1 diabetes. Pediatr Diabetes 2004; 5: 1619.
  • 14
    Bruno G, Cerutti F, Merletti F, Cavallo-Perin P, Gandolfo E, Rivetti M et al . Piedmont Study Group for Diabetes Epidemiology. Residual B-cell function and male/female ratio are higher in incident young adults than in children: the registry of Type 1 diabetes of the province of Turin, Italy, 1984–2000. Diabetes Care 2005; 28: 312317.
  • 15
    Sabbah E, Savola K, Ebeling T, Kulmala P, Vähäsalo P, Ilonen J et al . Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset Type 1 diabetes. Diabetes Care 2000; 23: 13261332.
  • 16
    Valdes AM, Thomson G, Erlich HA, Noble JA. Association between Type 1 diabetes age of onset and HLA among sibling pairs. Diabetes 1999; 48: 16581661.
  • 17
    Leslie RD, Delli Castelli M. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004; 53: 30333040.
  • 18
    Petrovsky N, Silva D, Schatz DA. Prospects for the prevention and reversal of Type 1 diabetes mellitus. Drugs 2002; 62: 26172635.
  • 19
    Herold KC. Achieving antigen-specific immune regulation. J Clin Invest 2004; 113: 346349.
  • 20
    Cooke A, Phillips JM, Parish NM. Tolerogenic strategies to halt or prevent Type 1 diabetes. Nat Immunol 2001; 2: 810815.
  • 21
    Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005; 206: 232259.
  • 22
    Gotfredsen CF, Buschard K, Frandsen EK. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985; 28: 933935.
  • 23
    Bowman MA, Campbell L, Darrow BL, Ellis TM, Suresh A, Atkinson MA. Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 1996; 45: 205208.
  • 24
    Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of Type I diabetes. Lancet 1993; 341: 927928.
  • 25
    Diabetes Prevention Trial—Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus. N Engl J Med 2002; 346: 16851691.
  • 26
    Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C et al . Effects of oral insulin in relatives of patients with Type 1 diabetes: the Diabetes Prevention Trial—Type 1. Diabetes Care 2005; 28: 10681076.
  • 27
    Pozzilli P. The DPT-1 trial: a negative result with lessons for future Type 1 diabetes prevention. Diabetes Metab Res Rev 2002; 18: 257259.
  • 28
    Staeva-Vieira T, Peakman M, Von Herrath M. Translational mini-review series on Type 1 diabetes: immune-based therapeutic approaches for Type 1 diabetes. Clin Exp Immunol 2007; 148: 1731.
  • 29
    Skyler JS. Prediction and prevention of Type 1 diabetes: progress, problems, and prospects. Clin Pharmacol Ther 2007; 81: 768771.
  • 30
    Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E et al . Pancreatic β-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for Type 1 diabetes. Diabetes Care 2004; 27: 23482355.
  • 31
    Kupila A, Sipilä J, Keskinen P, Simell T, Knip M, Pulkki K et al . Intranasally administered insulin intended for prevention of Type 1 diabetes—a safety study in healthy adults. Diabetes Metab Res Rev 2003; 19: 415420.
  • 32
    Achenbach P, Barker J, Bonifacio E; Pre-POINT Study Group. Modulating the natural history of Type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008 Apr; 8: 8793.
  • 33
    Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. β-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, doubleblind, phase II trial. Lancet 2001; 358: 17491753.
  • 34
    Schloot NC, Meierhoff G, Lengyel C, Vándorfi G, Takács J, Pánczél P et al . Effect of heat shock protein peptide DiaPep277 on ß-cell function in paediatric and adult patients with recent-onset diabetes mellitus Type 1: two prospective, randomised, double blind phase II trials. Diabetes Metab Res Rev 2007; 23: 276285.
  • 35
    Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R et al . Treatment of new-onset Type 1 diabetes with peptide DiaPep277 is safe and associated with preserved B-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007; 23: 292298.
  • 36
    Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D et al . Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed Type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007; 23: 286291.
  • 37
    Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmér M et al . Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 238246.
  • 38
    Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, Laupacis A et al . Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 13621367.
  • 39
    Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319: 599604.
  • 40
    Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T et al . Anti-thymocyte globulin and prednisone immunotherapy of recent onset Type 1 diabetes mellitus. Diabetes Res 1985; 2: 271276.
  • 41
    Harrison LC, Colman PG, Dean B, Baxter R, Martin FI. Increase in remission rate in newly diagnosed Type I diabetic subjects treated with azathioprine. Diabetes 1985; 34: 13061308.
  • 42
    Bougnères PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C et al . Limited duration of remission of insulin dependency in children with recent overt Type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39: 12641272.
  • 43
    Parving HH, Tarnow L, Nielsen FS, Rossing P, Mandrup-Poulsen T, Osterby R et al . Cyclosporine nephrotoxicity in Type 1 diabetic patients. A 7-year follow-up study. Diabetes Care 1999; 22: 478483.
  • 44
    Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of Type 1 diabetes. Lancet 2004; 363: 925931.
  • 45
    Pozzilli P, Visalli N, Signore A, Baroni MG, Buzzetti R, Cavallo MG et al . Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 1995; 38: 848852.
  • 46
    Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR non-binding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J Clin Invest 2003; 111: 409418.
  • 47
    Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD et al . The generation of a humanized, non-mitogenic CD3 monoclonal antibody, which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403411.
  • 48
    Chatenoud L, Bluestone J. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7: 622632.
  • 49
    Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005; 115: 29042913.
  • 50
    Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D et al . Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N Engl J Med 2002; 346: 16921698.
  • 51
    Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D et al . A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 2005; 54: 17531769.
  • 52
    Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al . Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N Engl J Med 2005; 352: 25982608.
  • 53
    Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by B-cell regeneration. J Clin Invest 2007; 117: 25532561.
  • 54
    Chatenoud L. Chemical immunosuppression in islet transplantation—friend or foe? N Engl J Med 2008; 358: 11921193.
  • 55
    Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet B-cell. Free Radic Biol Med 2006; 41: 177184.
  • 56
    The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with Type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517523.
  • 57
    Bonner-Weir S. Perspective: post-natal pancreatic B-cell growth. Endocrinology 2000; 141: 19261929.
  • 58
    Ablamunits V, Sherry NA, Kushner JA, Herold KC. Autoimmunity and β-cell regeneration in mouse and human Type 1 diabetes. The Peace Is Not Enough. Ann N Y Acad Sci 2007; 1103: 1932.
  • 59
    Noguchi H. Stem cells for the treatment of diabetes. Endocr J 2007; 54: 716.
  • 60
    Lock LT, Tzanakakis ES. Stem/progenitor cell sources of insulin-producing cells for the treatment of diabetes. Tissue Eng 2007; 13: 13991412.
  • 61
    Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 22702276.
  • 62
    Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem 2003; 278: 471478.
  • 63
    Garcia-Ocaña A, Takane KK, Syed MA, Philbrick WM, Vasavada RC, Stewart AF. Hepatocyte growth factor overexpression in the islet of transgenic mice increases β cell proliferation, enhances islet mass, and induces mild hypoglycemia. J Biol Chem 2000; 275: 12261232.
  • 64
    Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL et al . Effect of exenatide on B-cell function after islet transplantation in Type 1 diabetes. Transplantation 2007; 83: 2428.
  • 65
    Hogan A, Pileggi A, Ricordi C. Transplantation: current developments and future directions: the future of clinical islet transplantation as a cure for diabetes. Front Biosci 2008; 13: 11921205.
  • 66
    Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc 2007; 298: 194206.
  • 67
    Sutherland DE, Gruessner A, Hering BJ. Beta-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus: an integrated approach. Endocrinol Metab Clin North Am 2004; 33: 135148.
  • 68
    Ryan EA, Bigam D, Shapiro AM. Current indications for pancreas or islet transplant. Diabetes Obes Metab 2006; 8: 17.
  • 69
    Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM et al . Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 20602069.
  • 70
    Lü P, Liu F, Yan L, Peng T, Liu T, Yao Z et al . Stem cells therapy for Type 1 diabetes. Diabetes Res Clin Pract 2007; 78: 17.
  • 71
    Leslie RD, Williams R, Pozzilli P. Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91: 16541659.